Skip to main content
SpringerLink
Log in

Ertapenem cost saving for community-acquired IAI

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2012 euros

Reference

  • Grau S, et al. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis. Applied Health Economics and Health Policy : 12 Mar 2015. Available from: URL: http://doi.org/10.1007/s40258-015-0162-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ertapenem cost saving for community-acquired IAI. PharmacoEcon Outcomes News 724, 8 (2015). https://doi.org/10.1007/s40274-015-1986-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-1986-0

Search

Navigation